CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Extrawell Pharmaceutical Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Extrawell Pharmaceutical Holdings Ltd
Suites 2206-08, 22nd Floor, Devon House,
Taikoo Place, 979 King's Road,Quarry Bay
Phone: +852 28561918p:+852 28561918 Hong Kong Ticker: 858858
Business Summary
Extrawell Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Manufacturing segment is engaged in the development, manufacture and sales of pharmaceutical products. Its self-produced products include Transfer Factor Oral Solution, Wisk, ZhouBang and others. The Trading segment is engaged in the promotion and distribution of imported pharmaceuticals. Its imported products include Millibar and Skin Cap. The Gene Development segment is engaged in the commercial development and research, development of gene-related technologies.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer YiXie 59 12/5/2013 1/1/2001
Deputy Chief Executive Officer, Executive Director YongCheng 59 1/1/2021 12/5/2013
Executive Director, Company Secretary Sau KuenWong 59 9/30/2022 10/6/2008
7 additional Officers and Directors records available in full report.

Business Names
Business Name
858
Extrawell Pharmaceutical Holdings Ltd.
Jilin Extrawell Changbaishan Pharmaceutical Co., Ltd.

General Information
Number of Employees: 169 (As of 9/30/2023)
Outstanding Shares: 2,390,000,000 (As of 9/30/2023)
Shareholders: 1,955
Stock Exchange: HKG
Fax Number: +852 28563139


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024